Preventing Acarbose-induced Hepatic Injury

Autor:	Kazuya Ooi, Toshiya Katayama
Rok vydání:	2003
Předmět:	Hepatitis virus medicine.medical_specialty business.industry Disease medicine.disease Gastroenterology Endocrinology Diabetes mellitus Internal medicine Etiology medicine Alanine aminotransferase Lymphocyte stimulation business Normal range Acarbose medicine.drug
Zdroj:	Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 29:300-304
ISSN:	1882-1499 1346-342X
DOI:	10.5649/jjphcs.29.300
Popis:	An α-Glucosidase inhibitor, acarbose, offers a novel approach in the treatment of diabetes mellitus. Although several symptoms of the digestive system are known to be side effects of acarbose, severe hepatic disease has also been reported. In this case, the alanine aminotransferase (ALT) level was observed to progressively increase after the administration of acarbose. There is little doubt that the patient suffered a drug-induced hepatic injury. In order to clarify the etiology of this increase in ALT, a drug-induced lymphocyte stimulation test and hepatitis virus marker test were performed and the administration of acarbose was discontinued. All laboratory tests showed negative results, and at 40 days after the administration, the ALT level was found to be near the normal range. A clinical pharmacist should monitor the parameters to assess the response and to document the absence of any side effects.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3cec7e8840c9e34cbc7d8a1dabb6efdd https://doi.org/10.5649/jjphcs.29.300 Zobrazit plný text záznamu